InMode Ltd vs NeoGenomics Inc. Common Stock — how do they compare? InMode Ltd trades at $14.29 (market cap $821.73M), while NeoGenomics Inc. Common Stock trades at $17.17 (market cap $2.17B). The key difference: NeoGenomics Inc. Common Stock is far larger — about 2.6× InMode Ltd's market cap, and NeoGenomics Inc. Common Stock is trading nearer its 52-week high, InMode Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 28 Days and NeoGenomics Inc. Common Stock for 0 Days on average.
| INMD | NEO | |
|---|---|---|
Market Cap | $821.73M | $2.17B |
Volume | 337,645 | 1,615,943 |
Sector | Health | Health |
52-Week High | $16.62 | $19.91 |
52-Week Low | $12.76 | $7.19 |
Typical Hold Time | 28 Days | 0 Days |
Enterprise Value | $325.07M | $2.47B |
Signals from Pluang's Aura AI — not financial advice
InMode (INMD) trades at $14.305, up 0.03% today, with a bullish technical signal but mixed indicators. The company reported Q2 2026 revenue of $95.6M, consistent with the prior year, and maintains strong profitability with a net margin of 20.69%. Recent news includes the launch of Morpheus8 Cool and an unsolicited acquisition offer from Steel Partners at $16.75 per share.
The outlook is balanced: valuation appears attractive with a P/E of 11.8, but revenue stagnation and a recent earnings miss pose risks. Analyst sentiment is mixed with a slight hold bias. Upside potential exists from the acquisition offer and international growth, while cyclical softness and capital allocation concerns remain headwinds.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →